Bio-Thera Solutions, Ltd., headquartered in China, is a prominent biopharmaceutical company specialising in the development of innovative therapies for autoimmune diseases and oncology. Founded in 2010, the company has made significant strides in the industry, focusing on monoclonal antibodies and biosimilars that address unmet medical needs. With a strong presence in both domestic and international markets, Bio-Thera has established itself as a leader in the biopharmaceutical sector. Its core products, including the well-regarded BAT1806, exemplify the company's commitment to quality and efficacy, setting them apart from competitors. Recognised for its robust pipeline and strategic partnerships, Bio-Thera Solutions continues to enhance its market position, contributing to advancements in healthcare and improving patient outcomes globally.
How does Bio-Thera Solutions, Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bio-Thera Solutions, Ltd.'s score of 22 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bio-Thera Solutions, Ltd., headquartered in China, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there is no available data on their emissions or reduction initiatives, it is unclear how Bio-Thera Solutions, Ltd. is addressing climate change within its operations. The lack of reported emissions and targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting ambitious targets to align with global climate goals. However, without specific commitments or data from Bio-Thera Solutions, it is difficult to assess their position in this evolving landscape.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bio-Thera Solutions, Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
